However, in advanced cancer, using MEK inhibitors as a monotherapy can induce compensatory upregulation of pro-growth gene expression, leading to limited clinical outcomes in many Ras-driven cancers (Eleveld et al., 2015). This evidence concerns the gene MAP2K7 and cancer.